Patents Assigned to Beth Israel Deaconess Medical Center, Inc.
  • COMPOSITIONS AND METHODS FOR CHARACTERIZING A DNA REPAIR VARIANT POLYPEPTIDE
    Publication number: 20190002990
    Abstract: As described below, the present invention provides quantitative homologous recombination assays developed to characterize the pathogenicity DNA repair polypeptides (e.g., BRCA1, BRCA2, Rad51) and provide urgently needed functional information on the significance of DNA repair variants of uncertain significance (VUS) alleles. The invention also provides a method of generating site-specific recombination at a genomic locus or site-specific genome editing by inhibiting replication at the genomic locus, e.g., involving contacting the genomic locus with polypeptides that specifically bind target sequences at the genomic locus.
    Type: Application
    Filed: July 6, 2018
    Publication date: January 3, 2019
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Ralph Scully, Nicholas A. Willis
  • Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same
    Patent number: 10160788
    Abstract: The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: December 25, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Joseph Patrick Nkolola
  • TM4SF1 binding proteins and methods of using same
    Patent number: 10155812
    Abstract: This present invention relates to compounds (e.g., TM4SF1 binding proteins, e.g., anti-TM4SF1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of SEQ ID NO: 1. In particular, the compounds of the invention are capable of being internalized into a TM4SF1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of SEQ ID NO: 1. The invention also provides methods of treating a subject having a disorder associated with pathological angiogenesis with the compounds of the invention.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: December 18, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Shou-Ching S. Jaminet, Harold F. Dvorak
  • Identifying individual target sites for transcranial magnetic stimulation applications
    Patent number: 10137307
    Abstract: Techniques for identifying individual target sites for application of transcranial magnetic stimulation (TMS) to a brain of a patient for treatment of neurological and psychiatric disorders. The identification of the target TMS stimulation sites may be based on using functional connectivity magnetic resonance imaging (fMRI) to determine cortex regions of the brain that are functionally connected to other regions of the brain that may be stimulated to decrease symptoms of depression and other disorders. For example, target stimulation sites may be identified in the left dorsolateral prefrontal cortex (DLPFC) to remotely modulate the activity in a subgenual cingulate region and other limbic regions functionally connected with the DLPFC. TMS may be applied to the patient's head at the identified target TMS sites to treat depression and other neurological and psychiatric disorders.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 27, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alvaro Pascual-Leone, Michael D. Fox
  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10138479
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: November 27, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
    Patent number: 10137191
    Abstract: Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: November 27, 2018
    Assignees: Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
  • Measurement of FGF21 as a biomarker of fructose metabolism
    Patent number: 10132816
    Abstract: The invention provides, inter alia, methods of monitoring the fructose response of a subject by determining the level of fibroblast growth factor 21 (FGF21) gene expression product in a biological sample (such as a serum sample) from the subject, where the subject was previously administered a fructose bolus. The invention also provides methods of monitoring the response of a subject to a treatment for a disorder of metabolism, for discriminating fructose intolerance from other gastrointestinal disorders not associated with fructose intolerance, for identifying a subject at risk for developing a disorder of metabolism, as well as methods of treatment for a disorder of metabolism.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 20, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Eleftheria Maratos-Flier, Mark Herman, Jody Dushay, Ffolliott Martin Fisher
  • Devices for wound healing
    Patent number: 10130661
    Abstract: The present invention provides devices and methods for improving wound healing, in particular, in diabetic subjects.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: November 20, 2018
    Assignees: President and Fellows of Harvard College, Beth Israel Deaconess Medical Center, Inc., Trustees of Tufts College
    Inventors: Aristidis Veves, David J. Mooney, Jonathan Garlick
  • Methods for treating renal disease
    Patent number: 10130632
    Abstract: The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: November 20, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: David J. Friedman, Martin R. Pollak
  • Thrombospondin-1 polypeptides and methods of using same
    Patent number: 10125185
    Abstract: The invention features thrombospondin-1 (TSP-1) polypeptides (e.g., 3TSR-Fc fusion proteins), nucleic acid molecules encoding the TSP-1 polypeptides, and compositions thereof. The invention also features methods of making and using the TSP-1 polypeptides of the invention (e.g., using 3TSR-Fc fusion proteins to treat a subject having a disorder associated with pathological angiogenesis, e.g., cancer, e.g., epithelial ovarian cancer (EOC)).
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: November 13, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., University of Guelph
    Inventors: John W. Lawler, Mark Duquette, James Petrik
  • Recombinant adenoviruses and use thereof
    Patent number: 10106781
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: October 23, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Estimation of Descriptive Parameters from a Sample
    Publication number: 20180300453
    Abstract: An apparatus and method for generating a modified maximum-likelihood description of a system having a parent population of entities of different classes that includes collecting a sample population of the entities and measuring a statistical distribution of the sample population. The method further includes determining a modified maximum-likelihood estimate of the parent population based on the statistical distribution of the sample population and calculating a diversity measure of the estimated parent population to describe the system.
    Type: Application
    Filed: August 5, 2016
    Publication date: October 18, 2018
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ramy ARNAOUT, Joseph KAPLINSKY
  • Biomarkers and treatments for heart failure
    Patent number: 10100363
    Abstract: The invention features methods to predict the response to a cardiac therapy in a patient suffering from a cardiac disease, e.g., heart failure. The invention features measurement expression of biomarkers that help in this prediction. The invention also features methods for treatment of cardiac diseases. These methods include cardiac resynchronization therapy and miRNA based therapeutics.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: October 16, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Saumya Das
  • Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase
    Patent number: 10064853
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 4, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., The Broad Institute, Inc.
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
  • Sn-2-monoacylglycerols and lipid malabsorption
    Patent number: 10039742
    Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: August 7, 2018
    Assignees: Nestec S.A., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Bruce Bistrian, Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Celine Moulin
  • Methods for treating ischemia-reperfusion injury
    Patent number: 10028975
    Abstract: The present invention features methods for treating, reducing the likelihood of, or attenuating an ischemia-reperfusion injury in a subject by administering an inhibitor of spleen tyrosine kinase (Syk). Also included in the present invention are methods for identifying compounds that inhibit Syk for the treatment of an ischemia-reperfusion injury.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: July 24, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: George C. Tsokos
  • High throughput arrhythmia risk assessment using multilead residua signals
    Patent number: 10022060
    Abstract: A method and system for high-throughput prediction of the onset of heart arrhythmias observes trends in abnormal or pathologic morphology of the electrocardiogram (ECG). A first set of ECG signals is monitored from a patient. A baseline measurement is generated from the monitored first set of ECG signals to contain nonpathologic ECG morphologies in each lead. A second set of ECG signals is monitored from the patient and a second baseline measurement is generated from the second set of ECG signals. A residuum signal is generated for each lead based on the baseline measurement and the second baseline measurement. The residuum signals are averaged across the leads. R-wave heterogeneity, T-wave heterogeneity, P-wave heterogeneity, or ST-segment heterogeneity or other indicators of arrhythmia risk or myocardial ischemia are quantified based on the generated residuum signals and the averaged residuum signal.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: July 17, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Bruce D. Nearing, Richard L. Verrier
  • Compositions and methods for characterizing a DNA repair variant polypeptide
    Patent number: 10017825
    Abstract: As described below, the present invention provides quantitative homologous recombination assays developed to characterize the pathogenicity DNA repair polypeptides (e.g., BRCA1, BRCA2, Rad51) and provide urgently needed functional information on the significance of DNA repair variants of uncertain significance (VUS) alleles. The invention also provides a method of generating site-specific recombination at a genomic locus or site-specific genome editing by inhibiting replication at the genomic locus, e.g., involving contacting the genomic locus with polypeptides that specifically bind target sequences at the genomic locus.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: July 10, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Ralph Scully, Nicholas A. Willis
  • Prefabricated alginate-drug bandages
    Patent number: 10016524
    Abstract: The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: July 10, 2018
    Assignees: President and Fellows of Harvard College, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Cathal J. Kearney, Uyanga Tsedev, David J. Mooney, Aristidis Veves, Thomas Michael Braschler, Sidi A. Bencherif
  • Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
    Patent number: 10017563
    Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: July 10, 2018
    Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner